key: cord-0823999-zhwdicfm authors: Kittel, Maximilian; Findeisen, Peter; Muth, Maria-Christina; Thiaucourt, Margot; Gerhards, Catharina; Neumaier, Michael; Haselmann, Verena title: Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® Anti-SARS-CoV-2 immunoassay date: 2021-02-10 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.02.024 sha: b711d6abfae9696a5bb0707151b1c84d855e75f5 doc_id: 823999 cord_uid: zhwdicfm Background The detection of antibodies against the novel coronavirus SARS-CoV-2 is mandatory for the diagnosis, retrospective assessment of disease progression, and correct evaluation of the current infection situation in the population. Many of these assays have been launched by various manufacturers. Unfortunately, the new FDA emergency use regulations have resulted in a situation where laboratories have to perform their own validation studies. Numerous of these labs do not have the biobank needed to carry the studies out. Methods In this paper, we introduce a method that allows institutions to quickly perform a verifiation study in a low-prevalence infection situation. As proof of concept, we used the Roche Elecsys Anti-SARS-CoV-2 ECLIA assay and an SAP-based hospital information system. The Shenzhen YHLO Biotech IgM and IgG assay targetting other surface patterns, was used as confirmatory test. Results The Roche assay demonstrated a limit of detection of 0.069 COI (cutoff index) and successfully passed the performance validation according to CLSI EP15-A3. The study population of 627 in-patients exhibited an age median of 64 years and approximately 13% of the group were under intensive care at the respective time point. All included patients were tested negative for SARS-CoV-2 infection by qRT-PCR (cobas 6800®, Roche, Mannheim, Germany). Only one false positive result was obtained, resulting in a specificity for the Roche Elecsys Anti-SARS-CoV-2 test of 99.84% and a negative predictive value of 99.98%. Conclusions The anonymized use of residual material enables quick evaluation of anti-SARS-CoV-2 immunoassays, as shown in this work with the Roche Elecsys assay. Comparison of the control population with economic data makes it possible to validate the sampling set and therefore to determine diagnostic specificity. Using the chosen approach, it was shown that the Roche test achieved very good results in terms of diagnostic specificity, reproducibility and limit of detection. manufacturers. Unfortunately, the new FDA emergency use regulations have resulted in a situation where laboratories have to perform their own validation studies. Numerous of these labs do not have the biobank needed to carry the studies out. Methods (57) In this paper, we introduce a method that allows institutions to quickly perform a verifiation study in a low-prevalence infection situation. As proof of concept, we used the Roche Elecsys Anti-SARS-CoV-2 ECLIA assay and an SAP-based hospital information system. The Shenzhen YHLO Biotech IgM and IgG assay targetting other surface patterns, was used as confirmatory test. Results (86) The Roche assay demonstrated a limit of detection of 0.069 COI (cutoff index) and successfully passed the performance validation according to CLSI EP15-A3. The study population of 627 in-patients exhibited an age median of 64 years and approximately 13% of the group were under intensive care at the respective time point. All included patients were tested negative for SARS-CoV-2 infection by qRT-PCR (cobas 6800 ® , Roche, Mannheim, Germany) . Only one false positive result was obtained, resulting in a specificity for the Roche Elecsys Anti-SARS-CoV-2 test of 99.84% and a negative predictive value of 99.98%. The anonymized use of residual material enables quick evaluation of anti-SARS-CoV-2 immunoassays, as shown in this work with the Roche Elecsys assay. Comparison of the control population with economic data makes it possible to validate the sampling set and therefore to determine diagnostic specificity. Using the chosen approach, it was shown that the Roche test Whiting School of Engineering, 2020). For pandemic control, the identification and isolation of infected individuals is crucial, as is the assessment of seroprevalence to guide social restriction measures. COVID-19 testing can be principally divided into two approaches: the direct qRT-PCR-based detection of SARS-CoV-2 viral RNA using nucleic acid amplification tests (NAATs) from respiratory specimens collected with, e.g., nasopharyngeal swabs; and the indirect the detection of virus-specific antibodies in peripheral blood as an indicator of a former infection. NAATs are mostly limited to the early phase of infection , Kucirka et al., 2020 and their diagnostic value is limited by false-negative test results due to either preanalytical or analytical obstacles (Tu et al., 2020 , Wang W. et al., 2020 . The need to detect immunoreactivity against SARS-CoV-2 to diagnose a previous infection and to estimate seroprevalence at population level places immunoassays in the spotlight. Although currently available tests for detecting anti-SARS-CoV-2 antibodies have a high diagnostic sensitivity and specificity (Kohmer et al., 2020 , Kontou et al., 2020 , the positive predictive value is often very low because seroprevalence is still low (Bryant et al., 2020) . For example, given the seroprevalence of 0.301% in Germany, a test with a sensitivity of 99.5% and a specificity of 99.78% will result in a positive predictive value of 58%. This means that a person has a 42% J o u r n a l P r e -p r o o f chance of actually having no immune response to SARS-CoV-2. Assessing a test's specificity is therefore crucial to ensuring the diagnostic benefit (Neumaier, 2020) . Currently, no studies assessing the specificity of serological assays in a large population are available; in particular, the rate of cross-reactivity with other coronaviruses or with autoimmunological comorbidities such as rheumatoid arthritis or psoriasis presents a potential problem (Vinyé Bausà et al., 2020 . Another limitation is an insufficient understanding of antibody kinetics over time to distinguish potential immunity thresholds (Winter and Hegde) . Additionally, with its emergency use authorization (EUA), the FDA has drastically reduced manufacturer requirements for using serological test systems in patient care. This implies that the laboratories must perform their own validation studies before offering a serological assay (U.S. Food & Drug Administration, 2020). The large number of immunoassays on the market, the absence of a sufficient biobank, the difficult working conditions due to the ongoing pandemic, and the limited number of peer-reviewed publications all mean that these studies are a hughe task for laboratory physicians (Huang et al., 2020 , Security, 2020 . For introduction into routine care settings, tests must be high-throughput and have a short turnaround time. One such assay with FDA approval is the Roche Elecsys Anti-SARS-CoV-2 ECLIA (Roche Cobas ® , 2020) . Here, we present a strategy for simple, fast-track validation and performance verification of SARS-CoV-2 serological assays that requires no extensive biobanking and uses standard-of-care clinical samples as a prerequisite for introducing serological assays into routine care. This approach does not claim to replace extensive test validation as usually provided by the manufacturers, but allows the laboratory to get a clear indication of the test performance in terms of specificity. J o u r n a l P r e -p r o o f All blood samples were collected on July 2, 2020, at the University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany, as clinically indicated. After determination of the required laboratory parameters, residual blood samples were anonymized before anti-SARS-CoV-2 antibody detection. To verify the representativeness of the study population, the medical history was evaluated by a hospital information system database query (Cerner, IS-H*med, version 7.2.1). The ICD-10-coded main condition and the number of secondary diagnoses from all patients who were treated in the hospital on the day of testing were examined. Wards used as index wards for patients with suspected COVID-19 and for treatment of confirmed infections were excluded from the assessment. The gender, age, and treating medical department of all study participants were recorded. Anonymized use of residual patient material for test evaluation and method development was approved by the Institutional Review Board, and the study was conducted in accordance with the Declaration of Helsinki. Clotted serum samples or lithium heparin blood samples were centrifuged at 2,000 g for 10 minutes at 18°C within 4 hours of sample collection. Residual blood samples were analyzed after examination of requested standard-of-care laboratory testing. To avoid compromising the requirements of follow-up patient testing, samples with a residual volume of less than 1 ml serum/plasma were excluded. All antibody detections were performed using the Elecsys Anti-SARS-CoV-2 assay manufactured by Roche (Penzberg, Germany, reagent LOT number 496298 and 495464). This J o u r n a l P r e -p r o o f electrochemiluminescence immunoassay (ECLIA) detects anti-SARS-CoV-2 antibodies using a recombinant protein which represents the nucleocapsid antigen. This CE/IVD-marked assay is designed for detecting different antibody subclasses (IgM, IgA, and primarily IgG). The results are reported as cutoff index (COI), and COI results above 1.0 are interpreted as positive. The manufacturer does not specify a gray area or repeat range. Since no commercial controls were available at the time of the study, controls were prepared according to the manufacturer's instructions. The controls were analyzed in duplicates every eight hours during testing. All analyses were carried out on a Cobas e411 analyzer (Roche, Mannheim, Germany) . For all samples with COI values above 0.9, a confirmatory test was performed on an iFLASH 1800 using Shenzhen YHLO Biotech's IgM and/or IgG assay, a magnetic chemiluminescence immunoassay (CLIA) for the detection of IgM and IgG against the SARS-CoV-2 nucleocapsid protein and spike protein. This confirmation test detects alternative surface structures than the Roche assay and is only offered for the immunoglobulin subclasses and IgG and IgM. Within-run precision and total precision were evaluated using controls provided by the manufacturer with predefined COI (cutoff indices) values and one pooled serum near the cutoff. The target value determination for this serum sample was performed with a 10-fold serial measurement where the average value found was used as a target value. Precision evaluations were achieved by measuring the controls and serum sample five times for five consecutive days, in line with the protocol of the Clinical and Laboratory Standards Institute (CLSI EP15-A3). The model is easy to use and enables to verify the manufacturer's claims in terms of precision and reliability. The verification study was performed with five replicates per day for five days, whereupon imprecision estimates in terms of %CV within-run (repeatability) and %CV withinlaboratory were calculated and compared to the stated specifications. The multi-assay diluent and the positive control provided by the manufacturer were used to determine the limit of blank (LoB) and limit of detection (LoD) according to CLSI EP17-A2 using Abacus 2.0 (LABanalytics GmbH, www.labanalytics.de, 2016, Germany). The linearity evaluation was performed with a 12-fold serial dilution (1+1) of one patient sample with a very high initial COI (125.4). A serum pool of negative participants with an average COI of 0.0598 was chosen as the dilution medium. Data evaluation was performed according to CLSI EP-06A using Abacus 2.0 (LABanalytics GmbH, www.labanalytics.de, 2016, Germany). All statistical analyses were carried out using SPSS (IBM, 2019 , Version 25, 2017 , and pvalues below 0.05 were considered as significant. The assessment of test performance with CLSI models was carried out by the Excel plug-in Abacus 2.0 (LABanalytics GmbH, www.labanalytics.de, 2016, Germany). Diagrams and charts were plotted using GraphPad Prism version 7.0d (GraphPad Software, San Diego, CA, USA). The results of the performance evaluation regarding repeatability and intermediate precision were obtained using the five-day protocol set out in CLSI EP15-A3 and are summarized in Data obtained from the linearity assessment are displayed in Figure 2 . Results significantly deviated from the expected values (y = 0.1821x 3 -2.0682x 2 + 6.5411x -4.9006; R² = 0.9873; p < 0.05). Therefore, no linearity range can be defined. All patient samples that met the abovementioned inclusion criteria were included in the study. In order to protect the business data of our hospital, the query data can only be displayed in a highly abstracted form and mainly in proportions. The submitting departments were combined as far as possible. . The departments of internal medicine (INM) made up the largest share. The departments of visceral , orthopedic, trauma, and neurosurgery were combined and labeled SUR. The general pediatric department, pediatric surgery, and pediatric oncology were merged under KIDS. Urology, gynecology, dermatology, and ophthalmology were classed as UR/GY/DER/OPH. The other submitters were not further subdivided and were summarized as UDEF. Figure 2b shows the data obtained from the hospital information system for all patients treated at our hospital at time of the study, and the data from the patients who were included in our study. Here, a significant difference regarding age was revealed. Samples with a residual blood volume below 1 ml were excluded from anti-SARS-CoV-2 antibody testing, and this was most often the case for young children, which explains the age drift and the lower percentage of samples from KIDS. Figure 3 This shows a broad distribution with a focus on "C -malignant neoplasms," "I -circulatory system," and "Z -factors influencing health status and contact with health services" in the studie´s collective. This highlights the variability of clinical symptoms and diseases of patients treated at our hospital and included in the assessment of test specificity with our point prevalence approach. The Elecsys SARS-CoV-2 assay determined that 626 of the 627 samples were non-reactive. The mean value of these samples was 0.068 COI (median = 0.069 COI, SD = 0.031, and CV = 0.463%). None of the negatively measured samples were close to the manufacturer cutoffs ( Figure 5 ). In total, only one sample of the 627 tested was identified as positive with a COI of 63.47. The confirmation test with the Shenzhen YHLO Biotech assay showed a result below the manufacturer's cutoff of 10 AU/mL (IgM: 5.3 AU/mL, IgG: 5.06 AU/mL) for the detected antibody classes. This can be rated as a false-positive test result in our study population. With this data, a specificity of 99.84% (99.11 -100% 95% CI) could be determined. This would give a negative predictive value of 99.69% using the current prevalence of 0.314% for the state of Baden-Württemberg. Using prevalence data for Germany as a whole (0.301%), it would give a negative predictive value of 99.98%. Since the study design prevents the occurrence of truly positive cases in the test population, no statement can be made about positive predictive values or the sensitivity of the test method used. The diagnostic performance of the Elecsys Anti-SARS-CoV-2 assay has been evaluated in various studies , Chan et al., 2020 , Haselmann et al., 2020 , Hubbard et al., 2020 , Tan et al., 2020 , Trabaud et al., 2020 . It has demonstrated high overall diagnostic sensitivity and specificity, which range from 68.8% to 97.2% and from 99.05% to 100%, respectively. However, these clinical validation studies described so far rely on extensive blood sampling of infected individuals and especially of healthy volunteers, who are used as negative controls to assess the diagnostic specificity. In addition, there are also the validation data of over 10.000 J o u r n a l P r e -p r o o f samples that are provided by Roche in the assay instruction (Roche, 2020) . The validation approach for assessing diagnostic specificity in our study is the first that can be easily performed in any large-scale laboratory without the need for extensive blood sampling. It is a simple strategy that can be implemented promptly. This is of the upmost importance, given the huge societal and economic demand for fast, reliable, minimally invasive, and cost-efficient tests to safely detect a previous SARS-CoV-2 infection and immunity. Examining large sample sizes is the only way to detect individuals who were exposed to the virus and suffered only mild symptoms or were asymptomatic -these individuals represent the majority of cases (Kimball et al., 2020 , Lavezzo et al., 2020 , Mizumoto et al., 2020 , Oran and Topol, 2020 , Sutton et al., 2020 . The described approach allows the laboratory to conduct its own verification study within a short period of time. This allows to assess the test performance on its own and to initiate troubleshooting in case of major differences between the obtained data and those from the literature or provided by the manufacturer. A large-scale application of performant assays might make it possible to predict the "true prevalence" of the disease, since most patients develop detectable antibodies once the virus is no longer traceable in the upper respiratory tract by NAAT (Guo Li et al., 2020) .There still remains a diagnostic gap until the formation of antibodies, which is stated in the literature to be 2 weeks after symptom onset (Deeks et al., 2020) . Here, it is important to remember that even with excellent specificities, the significance of a test result depends on the positive/negative predictive value, and the calculation of this presupposes that the prevalence has been correctly determined. Irrespective of this, a falsepositive result would possibly give the individual a false sense of security regarding his or her humoral immune response status. The results produced with our methodology matched the manufacturer's stated test performance in terms of specificity. Evaluation of the control query in conjunction with the study results demonstrates that the Roche Elecsys Anti-SARS-CoV-2 assay provided an outstanding J o u r n a l P r e -p r o o f performance in "real-life" clinical conditions. While the vast majority of samples used by the manufacturer to determine specificity originate from routine diagnostics (n=6,305) and from blood donors (n=4,148), this study is the first to evaluate such a large sample size in a maximum-care hospital setting that therefore includes any type of comorbidity (Roche Cobas®, 2020) . Despite extensive literature research, the authors could not identify any studies that used a similarly large population to determine the specificity of the Roche assay. Although the Roche assay predominantly detects IgG antibodies, other antibody classes are also detected. This is due to the test technique. Several authors claim that it would be preferable not to use IgA and IgM for diagnostic purposes, as this can lead to false positives and therefore lower specificity (Van Elslande et al., 2020 , Wang Qiang et al., 2020 . We cannot agree on this with regard to the Roche assay. It seems that its ECLIA technology is capable of reproducing, under real conditions, the 99.81% specificity indicated by the manufacturer (Roche Cobas®, 2020 ). Nevertheless, our study approach has two major limitations. First, the chosen design means that we cannot provide a statement about the sensitivity of the test. However, this problem has already been sufficiently addressed by other authors and can only be clarified by longitudinal observations. Another limitation is that data privacy laws in Germany make it impossible to process personal data without a written declaration of consent. As this would have prevented the study from being carried out, the samples were processed anonymously. The validation of our sample was verified by a matching with the control data. Since all inpatient samples from the day that met the inclusion criteria were processed, it was not possible to achieve a higher number of cases. This could be overcome by a multicenter approach. Another limitation to be mentioned concerns the negative predictive value. Since this was determined on the base of a hospital population, it can only be applied to a comparable one. In J o u r n a l P r e -p r o o f addition, the study took place in summer, which results in a lower incidence of other respiratory viruses and consequently of a lower probability of cross-reactivities. One constraint we were unable to overcome due to the chosen anonymous study design was a dedicated follow-up of the false reactive test result. Of course, it must be considered that this particular patient could also have had a false negative NAAT result. However, this would seem unlikely due to the assay used, which has one of the highest sensitivities (Pujadas et al., 2020) . In conclusion, this study proves that the Roche Elecsys Anti-SARS-CoV-2 antigen detection assay is not compromised by most comorbidities occurring in hospital settings. Despite the current low prevalence of SARS-CoV-2, this test procedure seems to allow the implementation of high-throughput epidemiological investigations and provides a complimentary diagnostic approach to overcome the limitations of qRT-PCR tests for viral detection from respiratory material. The procedure presented in this study enables quick evaluation of these test methods in laboratories without biobanks. The anonymized use of residual material and comparison of the control population with abstracted economic data makes it possible to assess the validity of the random sampling and therefore to determine diagnostic specificity with the recommended sample size of 500 (Fang et al., 2020) . Important in implementing this ubiquitous rapid test validation strategy is the use of one or two independent confirmatory tests addressing different surface antigens. However, the limitation of double false-positive results remains, and increases with multiple pre-existing conditions and a higher number of people with previous infection. The limit of blank was determined by the 30x serialmeasurement of the manufacturers dilution medium. Subsequently, a series measurement with a very low concentration was carried out and the limit of detection was calculated accordingly. immunoassays for SARS-CoV-2: a head-to-head benchmark comparison Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures Antibody tests for identification of current and past infection with SARS-CoV-2. The Cochrane database of systematic reviews 2020 The Laboratory Diagnosis of COVID-19--Frequently-Asked Questions Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples Rapid establishment of a COVID-19 biobank in NHRI by National Biobank Consortium of Taiwan Comparison of two automated immunoassays for the detection of SARS-CoV-2 nucleocapsid antibodies Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility -King County Clinical performance of different SARS-CoV-2 IgG antibody tests Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo' Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test Elecsys Anti-SARS-CoV-2 Serology-based tests for COVID-19 Universal Screening for SARS-CoV-2 in Women Admitted for Delivery Comparative Clinical Evaluation of the Roche Elecsys and Abbott SARS-CoV-2 Serology assays for COVID-19 Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) 2020 Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients Cross-reactions between rheumatoid factor and IgM SARS-CoV-2 A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays Detection of SARS-CoV-2 in Different Types of Clinical Specimens The important role of serology for COVID-19 control. The Lancet Infectious Diseases We wish to thank Ruth Leiblein, Sonja Gepperth and Cornelia Mathis-Schwarz for helping to collect samples.J o u r n a l P r e -p r o o f The authors have no conflicts of interest to declare.